Arcus Biosciences Inc. (RCUS)
NYSE: RCUS
· Real-Time Price · USD
10.37
0.46 (4.64%)
At close: Aug 15, 2025, 3:59 PM
10.64
2.60%
After-hours: Aug 15, 2025, 07:29 PM EDT
Arcus Biosciences Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 160M | 28M | 26M | 48M | 39M | 145M | 31M | 32M | 29M | 25M | 33.66M | 33M | 27M | 18M | 354.5M | 9.46M | 9.46M | 9.46M |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 160M | 28M | 26M | 48M | 39M | 145M | 31M | 32M | 29M | 25M | 33.66M | 33M | 27M | 18M | 354.5M | 9.46M | 9.46M | 9.46M |
Operating Income | -8M | -122M | -103M | -105M | -106M | -16M | -91M | -80M | -83M | -86M | -74.44M | -70M | -69M | -67M | 281.27M | -78.14M | -76.14M | -72.75M |
Interest Income | 10M | 11M | 12M | 14M | 13M | 13M | 11M | 12M | 9M | 9M | 7.54M | 5M | 3M | n/a | n/a | 161K | 166K | 154K |
Pretax Income | -8M | -112M | -94M | -92M | -93M | -4M | -80M | -69M | -74M | -78M | -67.46M | -65M | -67M | -67M | 281.18M | -77.97M | -75.97M | -72.59M |
Net Income | -8M | -112M | -94M | -92M | -93M | -4M | -81M | -71M | -75M | -80M | -67.46M | -65M | -67M | -68M | 279.37M | -77.97M | -75.97M | -72.59M |
Selling & General & Admin | 29M | 28M | 28M | 30M | 30M | 32M | 29M | 30M | 28M | 30M | 27.9M | 26M | 26M | 24M | 23.3M | 16.34M | 16.83M | 15.82M |
Research & Development | 139M | 122M | 101M | 123M | 115M | 109M | 93M | 82M | 84M | 81M | 80.2M | 77M | 70M | 61M | 49.94M | 71.25M | 68.77M | 66.39M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | 20M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 168M | 150M | 129M | 153M | 145M | 161M | 122M | 112M | 112M | 111M | 108.1M | 103M | 96M | 85M | 73.23M | 87.6M | 85.6M | 82.21M |
Interest Expense | 2M | 1M | 2M | 1M | n/a | 1M | n/a | 1M | n/a | 1M | 563K | n/a | 1M | n/a | 260K | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 168M | 150M | 129M | 153M | 145M | 161M | 122M | 112M | 112M | 111M | 108.1M | 103M | 96M | 85M | 73.23M | 87.6M | 85.6M | 82.21M |
Income Tax Expense | n/a | n/a | 1M | n/a | n/a | n/a | 1M | 2M | 1M | 2M | -4K | n/a | n/a | 1M | 1.81M | n/a | n/a | n/a |
Shares Outstanding (Basic) | 106.1M | 98.4M | 91.7M | 91.4M | 91.1M | 86.2M | 75M | 74.6M | 73.2M | 73M | 72.6M | 72.2M | 71.8M | 71.19M | 70.4M | 70.11M | 69.75M | 67.08M |
Shares Outstanding (Diluted) | 106.5M | 98.4M | 91.7M | 91.4M | 91.1M | 86.2M | 75M | 74.6M | 73.2M | 73M | 72.6M | 72.24M | 71.81M | 71.19M | 75.36M | 70.11M | 69.75M | 67.08M |
EPS (Basic) | n/a | -1.14 | -1.03 | -1.01 | -1.02 | -0.05 | -1.08 | -0.95 | -1.02 | -1.1 | -0.92 | -0.84 | -0.9 | -0.96 | 3.97 | -1.11 | -1.09 | -1.08 |
EPS (Diluted) | n/a | -1.14 | -1.03 | -1.01 | -1.02 | -0.05 | -1.08 | -0.95 | -1.02 | -1.1 | -0.92 | -0.84 | -0.9 | -0.96 | 3.71 | -1.11 | -1.09 | -1.08 |
EBITDA | 4M | -108M | -89M | -89M | -91M | n/a | -77M | -67M | -72M | -75M | -65.42M | -63M | -64M | -66M | 281.92M | -77.01M | -75.15M | -71.79M |
EBIT | 2M | -111M | -92M | -91M | -93M | -3M | -80M | -68M | -74M | -77M | -66.9M | -65M | -66M | -67M | 281.92M | -77.97M | -75.97M | -72.59M |
Depreciation & Amortization | 2M | 3M | 3M | 2M | 2M | 3M | 3M | 1M | 2M | 2M | 1.48M | 2M | 2M | 1M | -441K | 963K | 820K | 800K |